Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma

Stewart, William C.; DuBiner, Harvey; Mundorf, Thomas K.; Laibovitz, Robert; Sall, Kenneth; Katz, L. Jay; Singh, Kuldev; Shulman, D. Geoffrey; Siegel, Les I.; Hudgins, Alison C; Nussbaum, Lawrence L.; Apostolaros, Maria

doi:10.1016/s0002-9394(98)00328-6

Cited by 37 publications

(18 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…50 A possible association between timolol eye drops and fetal cardiac arrhythmia was demonstrated by Wagenvoort et al 51 Previous data have also suggested that ␤-blockers have an adverse effect on HDL and total cholesterol. Studies have shown that topical timolol adversely affects the HDL and total cholesterol/HDL ratio, 52 and that the adverse effects of timolol on lipids are greater than those of carteolol. 53 Timolol eye drops have also been reported to cause severe bradycardia when taken with verapamil.…”

Section: Timololmentioning

confidence: 99%

Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension

Han¹,

Frishman²,

Sun³

et al. 2008

Cardiology in Review

View full text Add to dashboard Cite

Glaucoma and ocular hypertension are highly prevalent conditions in individuals over the age of 40 and are commonly seen together in patients with cardiovascular disease. Many of the antiglaucoma medications, when systemically absorbed, affect the sympathetic and parasympathetic nervous systems of patients and can cause cardiovascular toxicity. Such adverse effects are frequently associated with the long-term use of potentially toxic agents in elderly people, who are most prone to chronic eye disease. Moreover, patients may not associate their symptoms with the topical eye medications, and consequently may not report adverse drug effects. Drug-drug interactions can also occur when patients are taking medications for both cardiovascular disease and glaucoma. In this review, the systemic toxicity of these agents is reviewed, along with possible drug-drug interactions. Mention is made of other antiglaucoma medications used alone and in combination with topical beta-blockers. Identification of genetic loci-a bold new step toward glaucoma treatment-is mentioned briefly at the end of the article.

show abstract

Section: Timololmentioning

confidence: 99%

Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension

Han¹,

Frishman²,

Sun³

et al. 2008

Cardiology in Review

View full text Add to dashboard Cite

show abstract

“…Although carteolol is less irritating than 0.5% timolol but moderate corneal anaesthesia has been reported (Bartlett et al, 1999). Carteolol appears to have negligible effect on serum lipid profile (Stewart et al, 1999).…”

Section: Other Beta Antagonistsmentioning

confidence: 88%

“…This novel ophthalmic vehicle provides similar pressure lowering effect as the aqueous form with just once a day dosing . It is believed to reduce the possible systemic adverse effects but with higher reported incidence of transient blurring of vision (Dickstein et al, 2001;Stewart et al, 1999). Topical beta blockers are inexpensive especially in the generic form that further increased their popularity especially in developing countries.…”

Section: Beta Antagonistsmentioning

confidence: 99%

Pressure Lowering Medications

Tajudin¹,

Yaakub²

2011

Glaucoma - Current Clinical and Research Aspects

View full text Add to dashboard Cite

“…Carteolol has "intrinsic sympathomimetic activity" (ISA) and subsequently may have less effect on lipid profiles than other nonselected betablockers. [64][65][66] Only the generic version of carteolol is sold in the USA. There have been reports of anterior uveitis in patients using metipranolol, persisting even after its reformulation.…”

Section: Beta-adrenergic Antagonistsmentioning

confidence: 99%

“…138 The patient's lipid profile may be less affected with Ocupress, which has intrinsic sympathetic activity (ISA). 64 Topical beta-blockers can produce central nervous system effects including depression, anxiety, confusion, hallucinations, drowsiness, weakness, memory loss, impotence, and frail elderly patients can become "weak and dizzy." 139 Finally, alopecia has been reported with topical beta-blockers (package insert, Timoptic Ophthalmic Solution, Merck & Co., West Point, Pennsylvania.…”

Section: Beta-adrenergic Antagonistsmentioning

confidence: 99%

Medications Used to Treat Glaucoma

Schacknow

Samples

2010

The Glaucoma Book

View full text Add to dashboard Cite

ConclusionOptimal therapy for glaucoma would involve IOP control throughout the 24-h period. However, not all therapies are equally efficacious at all times of the day and night. Understanding of the mechanisms of action of different therapies, along with the knowledge of the circadian changes in aqueous humor dynamics, allows us to predict the therapies that will provide the most consistent IOP reduction. As well, understanding of aqueous humor dynamics may help in the development of future therapies with consistent 24-h IOP control. Bibliography

show abstract

Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma

Cited by 37 publications

References 17 publications

Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension

Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension

Pressure Lowering Medications

Medications Used to Treat Glaucoma

Contact Info

Product

Resources

About